Overview
C2N Diagnostics is a specialty diagnostics company focused on developing and commercializing blood-based biomarker tests for the early detection and monitoring of Alzheimer's disease and related neurodegenerative disorders. The company leverages proprietary high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodologies to identify and quantify protein biomarkers implicated in neurological disease pathology. C2N's flagship products, the PrecivityAD® and PrecivityAD2™ blood tests, measure amyloid pathology and tau-related biomarkers to aid in clinical diagnosis, treatment monitoring, and clinical trial enrollment. The company's mission centers on transforming neurodegenerative disease diagnosis through precision medicine approaches that provide accessible, minimally invasive alternatives to invasive imaging and cerebrospinal fluid testing.